A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas

NCT00521560 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Primary Non-Hodgkin-Lymphoma
Refractory Non-Hodgkin-Lymphoma
CD20+ Aggressive Non-Hodgkin's Lymphoma

Interventions

DRUG: Zevalin

Sponsor

Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH